Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients.
Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.
Company Details
- Employees
- 80
- Founded
- -
- Address
- 220, Boulevard Gonthier D'andernach, Illkirch-Graffenstaden,grand Est 67400,france
- Phone
- +33 3 90 40 61 50
- co****@****ics.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- domaintherapeutics.com
- Keywords
- GPCR, immuno-oncology, cancer, immunotherapy, clinical research, drug development, precision medicine, clinical trials, cancer research, biotechnology, drug discovery, life sciences, biopharma, innovation, sustainability, cancer treatment, immunosuppression, patient-centered approach, immune system, cancer immunotherapy, tumor biology, tumor microenvironment, immunoresistance, clinical development, biomarkers, soft mobility, green mobility, sustainable mobility, sustainable transportation, sustainable future, inflammation.
- HQ
- Illkirch-Graffenstaden, Grand Est
Domain Therapeutics Questions
Domain Therapeutics's helpline number is +33 3 90 40 61 50
Domain Therapeutics's website is domaintherapeutics.com
Domain Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/domain-therapeutics
Domain Therapeutics has
80 employees.
View email and phone details for 80
employees at Domain Therapeutics.
Domain Therapeutics's industry is
Pharmaceutical Manufacturing
Domain Therapeutics's top competitors are
Novalix,
Sartorius Polyplus,
Octapharma France,
Biovalley France,
Biosynex Pharma,
Polypeptide Group,
Inoviem Scientific,
Transgene,
Phaxiam Therapeutics,
Spartha Medical.
Domain Therapeutics's support email address is contact@domaintherapeutics.com
Domain Therapeutics's categories are Pharmaceutical Manufacturing
Domain Therapeutics's founding year is 2008
